NYSE · Biotechnology

NUVB (NUVB) Stock

$6.58 -1.28% NYSE: NUVB Healthcare

Valuation

MetricValue
Price$6.58
Market Cap$2.28B
P/E Ratio-8.15
P/B Ratio5.54
P/S Ratio10.22
EPS (TTM)$-0.60
52-Week High$9.75
52-Week Low$1.81
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-66.99%
ROA-34.45%
ROCE-69.61%
Gross Margin-338.10%
Operating Margin-338.10%
Net Margin-1.02%
Debt/Equity0.03
Current Ratio6.98

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$8.0M$63.0M
Operating Profit$-93.0M$-120.0M$-100.0M$-593.0M$-213.0M
Net Profit$-87.0M$-104.0M$-76.0M$-568.0M$-205.0M
EPS$-0.44$-0.48$-0.35$-2.11$-0.60
Op Margin———-7527.3%-338.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$776.0M$672.0M$621.0M$541.0M$595.0M
Total Liabilities$30.0M$17.0M$16.0M$77.0M$289.0M
Cash$132.0M$101.0M$43.0M$36.0M$164.0M
Borrowings$3.0M$4.0M$4.0M$9.0M$10.0M

Latest News

Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level? Insider Monkey · Jul 13, 2026 RBC Capital Adjusts Nuvation Bio Price Target to $19 From $20, Maintains Outperform Rating MT Newswires · Jul 7, 2026 Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering PR Newswire · Jul 6, 2026 Is Nuvation Bio’s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative? Simply Wall St. · Jul 2, 2026 Doctor-turned-dealmaker reveals his M&A playbook Pharma Voice · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-68.0M$-96.0M$-68.0M$-130.0M$-173.0M
Investing Cash Flow$-455.0M$63.0M$9.0M$123.0M$99.0M
Financing Cash Flow$626.0M$1.0M$1.0M$0$0
Net Cash Flow$103.0M$-31.0M$-58.0M$-7.0M$128.0M
Free Cash Flow$-68.0M$-96.0M$-68.0M$-131.0M$-174.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-8.62%
Quick Ratio7.24
Interest Coverage-15.21
Return 1Y178.72%
Return 3Y242.93%
Return 5Y-23.93%

Ownership

Insiders Held18.59%
Institutions Held64.86%
Institutions Float Held79.67%
Institutional HolderSharesReport Date
FMR, LLC51,989,5932026-03-31
Decheng Capital LLC25,954,4392026-03-31
Blackrock Inc.25,100,3742026-03-31
Vanguard Capital Management LLC11,626,1982026-03-31
Omega Fund Management, Llc8,081,0892026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABCL $6.93 +6.13% -5.91 $2.12B 0.00%
AUPH $15.00 -1.19% 7.46 $1.93B 0.00%
CLDX $35.80 +0.63% -7.84 $2.38B 0.00%
EWTX $43.52 -2.03% -14.63 $4.68B 0.00%
GPCRStructure Therapeutics Inc. $53.36 -3.23% -20.21 $3.07B 0.00%

About NUVB

NUVB is led by CEO David T. Hung, employs 273 people, headquartered in US, publicly traded since 2020.

NUVB stock trades at $6.58 with a market capitalization of $2.28B. The stock is valued at a price-to-earnings (P/E) ratio of -8.15, price-to-book of 5.54, price-to-sales of 10.22. Over the past 52 weeks the stock has ranged between $1.81 and $9.75, and currently trades 32.5% below its 52-week high.

On profitability, NUVB generates a return on equity (ROE) of -66.99%, return on capital employed of -69.61%, an operating margin of -338.10%, a net profit margin of -1.02%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides